| Catalog No. | HY065046 |
| Brand | abinScience |
| Tested applications | FCM |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Isotype | IgG1-kappa |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | MSK8, VNRA, Vitronectin receptor, Integrin alpha-V, Vitronectin receptor subunit alpha, CD51, ITGAV, VTNR, ITGB6, Integrin beta-6 |
| References | 1. Crunkhorn S. Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy. Nat Rev Drug Discov. 2012 Mar 30;11(4):260. [HY065046] 2. Lo DJ, et al. Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant. 2013;13(12):3085-3093. [HY065046] 3. Wesam Elhawabri. REGULATION OF TGF-β1–INDUCED EPITHELIAL–MESENCHYMAL TRANSITION BY INTEGRIN INHIBITION. [HY065046] 4. Sylvers PH, et al. Mitigation of harmful algal blooms caused by Alexandrium catenella and reduction in saxitoxin accumulation in bivalves using cultivable seaweeds. Harmful Algae. 2021;105:102056. [HY065046] 5. Raghu G, et al. Randomized Phase IIa Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 Nov 1;206(9):1166-1168. View More [HY065046] |
| Purification | Protein A/G purified from cell culture supernatant. |
| Biological activity | STX-100 (1 h pretreatment) exhibits minimal inhibitory effects on TGF-β1-induced morphological and nuclear changes in A549 cells [3]. STX-100 (1 h pretreatment) does not substantially alter actin cytoskeletal organization in A549 cells and does not prevent TGF-β1-associated changes in actin distribution [3]. STX-100 (1 h pretreatment) has limited inhibitory effects on TGF-β1-induced morphological and nuclear changes in MCF10A cells [3]. STX-100 (1 h pretreatment) does not reverse TGF-β1-induced changes in cell organization, cell-cell adhesion, nuclear morphology, or extracellular matrix structure in MCF10A cells [3]. STX-100 (1 h pretreatment) does not substantially alter TGF-β1-driven changes in fibronectin fibril organization in MCF10A cells [3]. STX-100 (3 mg/kg; s.c.; weekly; 8 weeks) promotes acute renal allograft rejection in rhesus macaques [2]. |
| Endotoxin level | < 10 EU/mg |
| Expression system | Mammalian cells |
| Accession | P06756 & P18564 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | Bispecific, STX-100, STX100, STX100 |
| Clone ID | STX-100 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
Anti-Human αVβ6 Reference Antibody (STX-100, RUO)
Overview
Images
 SDS-PAGE |
SDS-PAGE for Research Grade Anti-Human Integrin AVB6 (ITGAV & ITGB6) Antibody (STX-100) |
 Flow cytometry |
Flow-cytometry using anti-human ITGB6 antibody. HT29 cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human ITGB6 monoclonal antibody (Catalog HY065046, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer. |